MedPath

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Phase 2
Completed
Conditions
Osteoarthritis, Knee
Interventions
Registration Number
NCT00041756
Lead Sponsor
Procter and Gamble
Brief Summary

Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Detailed Description

Matrix metalloproteinases have been implicated in the cartilage degradation that occurs in osteoarthritis. PG-530742 inhibits some of these matrix metalloproteinases, thus potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
395
Inclusion Criteria
  • mild to moderate knee osteoarthritis confirmed by a radiographic technique.
Exclusion Criteria
  • secondary knee osteoarthritis;
  • diseases other than osteoarthritis that could cause knee pain;
  • any disease or intervention (surgery, intra-articular injection) that would have an impact on knee pain or mobility;
  • drugs that act potentially on the bone or cartilage component of the knee joint.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo tablet
25 mg PG-530742PG-53074225 mg PG-530742
100 mg PG-530742100 mg PG-530742100 mg PG-530742
50 mg PG-53074250 mg PG-53074250 mg PG-530742
200 mg PG-530742200 mg PG-530742200 mg PG-530742
Primary Outcome Measures
NameTimeMethod
Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatmentbaseline and 12 months

The structural primary efficacy endpoint is the 1-year change from baseline in minimum joint space width (JSW) in the medial compartment of the tibiofemoral joint of the signal knee, as measured by microfocal knee radiographs obtained in the semi-flexed position.

Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 1 Yearbaseline and 12 months

The symptomatic primary efficacy endpoint is the change in total WOMAC scores after 1 year of treatment. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), Physical Function (17 items). The WOMAC uses descriptors for all items: none, mild moderate, severe, and extreme (corresponding to an ordinal scale of 0-4.) Scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. The total WOMAC score is created by summing the items for all three subscales (min=0, max=96)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Rehabilitation Hospital, Gizella telep

🇭🇺

Visegrad, Gizella telep, Hungary

The Medical Centre, Kingston Avenue

🇬🇧

East Horsley, Surrey, United Kingdom

The Crouch Oak Practice, 45 Station Road, Addlestone

🇬🇧

Addlestone, Surrey, United Kingdom

Orthopedic Clinic, Karolina ut 17

🇭🇺

Budapest, Hungary

Bridge House Medical Centre, Scholars Lane

🇬🇧

Stratford-upon-avon, Warwickshire, United Kingdom

Pound Hill Surgery, 1 Crawley Lane, Pound Hill

🇬🇧

Crawley, West Sussex, United Kingdom

Synexus Reading Clinical Research Centre, Whiteley Glebe, 11 Glebe Road, off Christchurch Gardens

🇬🇧

Reading, United Kingdom

National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology IV., Frankel Leo u. 38-40

🇭🇺

Budapest, Hungary

Rheumatology Department, Fourth Floor, Thomas Guy House, St Guy's House

🇬🇧

London Bridge, United Kingdom

Grosvenor Medical Centre Clinical Trials Unit, 18 upper Grosvenor Road, Tunbridge Wells

🇬🇧

Kent, United Kingdom

Dept of Rheumatology Dulwich Hospital, East Dulwich

🇬🇧

London, United Kingdom

Szent Ferenc Hospital, Department of Rheumatology, Csabai Kapu 42.

🇭🇺

Miskolc, Hungary

95 Stanwell Road

🇬🇧

Ashford, Middlesex, United Kingdom

Royal National Orthapaedic Hsopital, Brackley Hill

🇬🇧

Stanmore, Middlesex, United Kingdom

St Thomas Hospital, Lambeth Place Road

🇬🇧

London, Se17eh, United Kingdom

Synexus Wrightington, Wrightington Hospital, Hall Lane, Awpley Bridge

🇬🇧

Wigan, United Kingdom

National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology and Immunology, Frankel Leo u. 38-40

🇭🇺

Budapest, Hungary

Petz A. Country Hospital, Department of Rheumatology, Hid utca 2.

🇭🇺

Gyor, Hid Utica 2, Hungary

Synexus Birmingham Clinical Research Centre, Birmingham Research Park

🇬🇧

Edgbaston, United Kingdom

National Institute of Rheumatology and Physiotherapy, Dept. of Rheumatology I and Metabolic Osteology, Frankel Leo u. 38-40

🇭🇺

Budapest, Hungary

Hildenborough Medical Group, Trenchwood Surgery, 264 Shipbourne Road

🇬🇧

Tonbridge, United Kingdom

Dept of Rheumatology Selly Oak Hospital, Raddleburn Road, Selly Oak

🇬🇧

Birmingham, United Kingdom

Dept of Rheumatology Whipps Cross University Hospital, Whipps Cross Road

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath